The Company expects that cash, cash equivalents and investment securities of $328.1 million at September 30, 2017 along with the $162 million of net proceeds from the public offering of its common stock in October 2017 will be used primarily to advance the lumateperone development program, including to fund clinical trials of lumateperone in bipolar depression, behavioral disturbances in patients with dementia, depressive disorders and other lumateperone clinical trials and related clinical and non-clinical activities; to fund pre-commercial activities for lumateperone for the treatment of schizophrenia and bipolar disorder and, if lumateperone receives regulatory approval, initial commercialization efforts; to fund pre-commercial activities for lumateperone for the treatment of behavioral disturbances in patients with dementia, including Alzheimer’s disease; to fund pre-clinical and clinical development of the Company’s ITI-007 long-acting injectable program; and to fund non-clinical activities, including the continuation of manufacturing activities, in connection with the development of lumateperone. Funds will also be used for other clinical and pre-clinical programs, including the Company’s phosphodiesterase (PDE) development activities.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| ITI-007 updates | 17 | 1891 | March 4, 2017 | |
| Intra-Cellular Therapies corporate update | 0 | 277 | November 5, 2019 | |
| Intra-Cellular pulls off $150M funding as it preps schizophrenia drug filing | 3 | 636 | October 3, 2017 | |
| Intra-Cellular Therapies Presents Data Supporting the Potential for Potent and Rapid Antidepressant Activity with Lumateperone | 2 | 658 | May 8, 2017 | |
| Intracellular Theraputics reports mixed results with Lumateperone in Bipolar | 0 | 272 | July 8, 2019 |